Literature DB >> 7869047

T cell and non-T cell compartments can independently determine resistance to Leishmania major.

A H Shankar1, R G Titus.   

Abstract

In experimental murine cutaneous leishmaniasis caused by Leishmania major (Lm), the cellular determinants governing development of protective or exacerbative T cells are not well understood. We, therefore, attempted to determine the influence of T cell and non-T cell compartments on disease outcome. To this end, T cell chimeric mice were constructed using adult thymectomized lethally irradiated, bone marrow-reconstituted (ATXBM) animals of genetically resistant, C57BL/6, or susceptible, BALB/c, backgrounds. These hosts were engrafted with naive T cell populations from H-2-congenic susceptible, BALB.B6-H-2b, or resistant, C57BL/6.C-H-2d, animals, respectively. Chimeric mice were then infected with Lm, and disease outcome was monitored. BALB/c T cell chimeric mice, BALB/c ATXBM hosts given naive C57BL/6.C-H-2d T cells, resolved their infections as indicated by reductions in both lesion size and parasite numbers. Furthermore, the mice developed typical Th1 (interferon[IFN]-gamma hiinterleukin[IL]-4lo) cytokine patterns. In contrast, both sham chimeric, BALB/c ATXBM hosts given naive BALB/c T cells, and control irradiated euthymic mice succumbed to infection, producing Th2 profiles (IFN-gamma loIL-4hiIL-10hi). C57BL/6 T cell chimeras, C57BL/6 ATXBM hosts given naive BALB.B6-H-2b T cells, resolved their infections as did C57BL/6 sham chimeras and euthymic controls. Interestingly, whereas C57BL/6 control animals produced Th1 cytokines, chimeric animals progressed from Th0 (IFN-gamma hiIL-4hiIL-10hi) to Th2 (IFN-gamma loIL-4hiIL-10hi) cytokine profiles as cure ensued. Both reconstitution and chimeric status of all mice were confirmed by flow cytometry. In addition, T cell receptor V beta usage of Lm-specific blasts was determined. In all cases, V beta use was multiclonal, involving primarily V beta 2, 4, 6, 8.1, 8.2, 8.3, 10, and 14, with relative V beta frequencies differing between H-2b and H-2d animals. Most importantly, however, these differences did not segregate between cure and noncure outcomes. These findings indicate that: (a) genetic traits determining cure in Lm infection can direct disease outcome from both T cell and non-T cell compartments; (b) the presence of the curing genotype in only one compartment is sufficient to confer cure; (c) curing genotype T cells autonomously assume a Th1 cytokine profile-mediating cure; (d) noncuring genotype T cells can mediate cure in a curing environment, despite the onset of Th2 cytokine production; and lastly, (e) antigen specificity of responding T cells, as assessed by V beta T cell receptor diversity, is not a critical determinant of disease outcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7869047      PMCID: PMC2191940          DOI: 10.1084/jem.181.3.845

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  85 in total

Review 1.  Murine graft-versus-host disease across minor barriers: immunosuppressive aspects of natural suppressor cells.

Authors:  J H Holda; T Maier; H N Claman
Journal:  Immunol Rev       Date:  1985-12       Impact factor: 12.988

2.  Genetically determined susceptibility to Leishmania tropica infection is expressed by haematopoietic donor cells in mouse radiation chimaeras.

Authors:  J G Howard; C Hale; F Y Liew
Journal:  Nature       Date:  1980-11-13       Impact factor: 49.962

Review 3.  Immunology of leishmaniasis.

Authors:  F Y Liew; C A O'Donnell
Journal:  Adv Parasitol       Date:  1993       Impact factor: 3.870

4.  Analysis of subpopulations of glass-adherent mouse skin cells controlling resistance/susceptibility to infection with Leishmania tropica, and correlation with the development of independent proliferative signals to Lyt-1+/Lyt-2+ T lymphocytes.

Authors:  R M Gorczynski; S MacRae
Journal:  Cell Immunol       Date:  1982-02       Impact factor: 4.868

5.  Single gene control of resistance to cutaneous leishmaniasis in mice.

Authors:  L J DeTolla; P A Scott; J P Farrell
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

6.  B220: a B cell-specific member of th T200 glycoprotein family.

Authors:  R L Coffman; I L Weissman
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

7.  Inhibition of murine T cell-mediated cytolysis and T cell proliferation by a rat monoclonal antibody immunoprecipitating two lymphoid cell surface polypeptides of 94 000 and 180 000 molecular weight.

Authors:  M Pierres; C Goridis; P Golstein
Journal:  Eur J Immunol       Date:  1982-01       Impact factor: 5.532

Review 8.  T-cell and cytokine responses in leishmaniasis.

Authors:  S G Reed; P Scott
Journal:  Curr Opin Immunol       Date:  1993-08       Impact factor: 7.486

9.  Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing.

Authors:  D Davignon; E Martz; T Reynolds; K Kürzinger; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

10.  Immunological regulation of experimental cutaneous leishmaniasis. 1. Immunogenetic aspects of susceptibility to Leishmania tropica in mice.

Authors:  J G Howard; C Hale; W L Chan-Liew
Journal:  Parasite Immunol       Date:  1980       Impact factor: 2.280

View more
  18 in total

1.  Priming of a beta-galactosidase (beta-GAL)-specific type 1 response in BALB/c mice infected with beta-GAL-transfected Leishmania major.

Authors:  H R Chakkalath; A A Siddiqui; A H Shankar; D E Dobson; S M Beverley; R G Titus
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  An in vitro model for infection with Leishmania major that mimics the immune response in mice.

Authors:  M B Soares; J R David; R G Titus
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)--relation to Th1- and Th2-derived cytokines.

Authors:  Y Tokano; S Morimoto; H Kaneko; H Amano; K Nozawa; Y Takasaki; H Hashimoto
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

5.  CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice.

Authors:  V Julia; N Glaichenhaus
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

6.  Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice.

Authors:  H Nagai; Y Ueda; T Ochi; Y Hirano; H Tanaka; N Inagaki; K Kawada
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

7.  Characterization of an I-E-restricted, gp63-specific, CD4-T-cell clone from Leishmania major-resistant C3H mice that secretes type 2 cytokines and exacerbates infection with L. major.

Authors:  Cynthia M Theodos; Robin V Morris; Jeanette V Bishop; Jeremy D Jones; W Robert McMaster; Richard G Titus
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Insulin-like growth factor I is a growth-promoting factor for Leishmania promastigotes and amastigotes.

Authors:  H Goto; C M Gomes; C E Corbett; H P Monteiro; M Gidlund
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 9.  Production and function of cytokines in natural and acquired immunity to Candida albicans infection.

Authors:  R B Ashman; J M Papadimitriou
Journal:  Microbiol Rev       Date:  1995-12

10.  Monocyte subpopulations as important biomarkers of resistence and susceptibility during experimental infection with Leishmania (Leishmania) major.

Authors:  Tassiane Assiria Fontes Martins; Vitor Silva Barbosa; Gregório Guilherme Almeida; Lis Ribeiro Do Valle Antonelli; Wagner Luiz Tafuri; David M Mosser; Ricardo Gonçalves
Journal:  Biomed Pharmacother       Date:  2018-09-05       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.